Westborough, MA, United States

United Medical Systems

www.ums-usa.com/
Westborough, MA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 9, 2017
Site: www.businesswire.com

WESTBOROUGH, Mass.--(BUSINESS WIRE)--United Medical Systems (DE), Inc. (UMS) together with its parent, New State Capital Partners, LLC, announce they have invested in American Kidney Stone Management, LTD (AKSM) of Columbus, Ohio. The partnership with AKSM establishes UMS as the leading national provider of ESWL service with more than 75,000 procedures performed annually. “We are excited to continue working towards our goal of building a national urology services company and feel the merger of these two leading ESWL providers is the optimal way to increase the support of our urology partners. By increasing access to superior technology, we are providing the best kidney stone management available in the market,” said Jorgen Madsen, UMS Chief Executive Officer. “The blending of these two industry leading lithotripsy companies will take the process of kidney stone care to a new level. With the expertise of our clinical specialists and urology partners, we will ensure that our customers receive the highest level of care available in the market today.” Alan Buergenthal, AKSM Chief Executive Officer, added, “The timing of this transaction with UMS couldn’t be better. We are proud to combine our expertise with UMS’ to offer the latest technology to our physician partners, and together, we can provide urology patients the best urological care available in the market. The combination of these two industry leaders will be unsurpassed.” UMS provides affordable, advanced mobile medical services. Their unique transportable platform offers the appearance of a full-time, in-house program, without incurring the cost and burden associated with a fixed program. United Medical Systems pioneered the concept of shared mobile medical services for Urology, including Lithotripsy, BPH and ureteral stone laser treatment, MR/Fusion for prostate biopsy, and Stereotactic Breast Biopsy, and has become an international leader by partnering with medical facilities ranging from hospitals, ambulatory surgery centers and physician offices to medical equipment manufacturers. UMS is an internationally recognized company servicing over 850 facilities across the United States, as well as operating in Canada and South America. AKSM has over two decades of experience providing lithotripsy services to approximately 1,500 physicians in the United States through its urologist ownership program. Founded in Columbus Ohio, AKSM has grown to be one of the most trusted providers by providing the highest clinical quality and reliable service in kidney stone lithotripsy and other related treatment modalities. AKSM’s turnkey package brings management expertise, financial stability, industry leading technology and procedural outcomes monitoring to its physicians and customers. New State Capital Partners, LLC is an entrepreneurial-minded private equity firm that strives to be more nimble, more decisive and more cooperative than larger, institutional firms. New State prides itself on a long-term outlook, approaching each potential investment as an opportunity to create lasting and valuable relationships, rather than as an exercise in meeting rigid investing criteria. The firm is very flexible about the structure of its investment and focuses on growth and add-on investment. New State invests in market-leading companies with $8 million to $30 million of EBITDA in the areas of business services, healthcare services and industrials, and has in excess of $370 million in assets under management.


Davies M.A.,United Medical Systems
Advances in Pharmacology | Year: 2012

The prevention and treatment of brain metastases is an increasingly important challenge in oncology. Improved understanding of the molecular pathogenesis of a number of cancers has led to the development of highly active targeted therapies for patients with specific oncogenic events. Such therapies include EGFR inhibitors for lung cancer, HER2/neu inhibitors for breast cancer, and BRAF inhibitors for melanoma. This review will discuss the development of these targeted therapy approaches, existing data about their role in the management of brain metastasis, and opportunities and challenges for future research in this critical area. © 2012 Elsevier Inc.


Patent
Fujifilm Co. and United Medical Systems | Date: 2013-06-10

A system and method of labeling orthogonal or otherwise spatially related image views and related images is provided. The present invention provides automated progression for the labeling of vertebral and inter-vertebral regions, propagation of labels between views and images within a series, centering of label regions relative to the spine, circular lists of predefined labels, and label displays for individual slices of an orthogonal or axial view as a user scrolls through the plurality of image slices of the given view. In a further aspect, the present invention provides automated labeling of vertebral and inter-vertebral regions when a user provides labels for the adjacent two inter-vertebral or vertebral regions.


Patent
Fujifilm Co. and United Medical Systems | Date: 2014-07-14

The present invention is directed in general to imaging technologies and more particularly to medical imaging and picture archiving and communication systems (PACS) having an image display wherein system features and functions are provided to a user via active overlays located over displayed images. A system and method are provided to imbed an ability to interact with an image by activating traditional annotations that are displayed in conjunction with an image in a PACS. Users are able to access program functionalities in an improved, quicker, accurate and more intuitive means. More specifically, the present invention relates to providing the capability to customize multiple context menus, and flatten the command hierarchy of an imaging system. The present invention also provides the ability to overload current text and graphic annotations that are already displayed within an image of interest.


Kwong L.N.,University of Houston | Davies M.A.,United Medical Systems | Davies M.A.,University of Houston
Oncogene | Year: 2014

The treatment of melanoma, the most aggressive form of skin cancer, is being revolutionized by the development of personalized targeted therapy approaches. Mutant-selective BRAF inhibitors and MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients. However, emerging understanding of the molecular heterogeneity of this disease and the identification of multiple mechanisms of resistance to targeted therapies strongly support the rationale for combinatorial approaches. In this review, we will discuss the preclinical and clinical studies that are testing leading hypotheses and emerging combinatorial strategies for the future. © 2014 Macmillan Publishers Limited.


Hernandez-Aya L.F.,University of Miami | Gonzalez-Angulo A.M.,United Medical Systems
Oncologist | Year: 2011

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) network plays a key regulatory function in cell survival, proliferation, migration, metabolism, angiogenesis, and apoptosis. Genetic aberrations found at different levels, either with activation of oncogenes or inactivation of tumor suppressors, make this pathway one of the most commonly disrupted in human breast cancer. The PI3K-dependent phosphorylation and activation of the serine/threonine kinase AKT is a key activator of cell survival mechanisms. The activation of the oncogene PIK3CA and the loss of regulators of AKT including the tumor suppressor gene PTEN are mutations commonly found in breast tumors. AKT relieves the negative regulation ofmTORto activate protein synthesis and cell proliferation through S6K and 4EBP1. The common activation of the PI3K pathway in breast cancer has led tothe development of compounds targeting the effector mechanisms of the pathway including selective and pan-PI3K/pan-AKT inhibitors, rapamycin analogs for Mtor inhibition, and TOR-catalytic subunit inhibitors. The influences of other oncogenic pathways such as Ras-Raf-Mek on the PI3K pathway and the known feedback mechanisms of activation have prompted the use of compounds with broader effect at multiple levels and rational combination strategies to obtain a more potent antitumor activity and possibly a meaningful clinical effect. Here, we review the biology of the network, its role in the development and progression of breast cancer, and the evaluation of targeted therapies in clinical trials. © AlphaMed Press.


Davies M.A.,United Medical Systems
Cancer Discovery | Year: 2014

Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF V600 proteins. Characterization of a patient with concurrent BRAF -mutant melanoma and NRAS -mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy. © 2014 American Association for Cancer Research.


Lannon C.M.,United Medical Systems
Pediatrics | Year: 2013

Multiple gaps exist in health care quality and outcomes for children, who receive <50% of recommended care. The American Board of Pediatrics has worked to develop an improvement network model for pediatric subspecialties as the optimal means to improve child health outcomes and to allow subspecialists to meet the performance in practice component of Maintenance of Certification requirements. By using successful subspecialty initiatives as exemplars, and features of the Institute for Healthcare Improvement's Breakthrough Series model, currently 9 of 14 pediatric subspecialties have implemented collaborative network improvement efforts. Key components include a common aim to improve care; national multicenter prospective collaborative improvement efforts; reducing unnecessary variation by identifying, adopting, and testing best practices; use of shared, valid, high-quality real-time data; infrastructure support to apply improvement science; and public sharing of outcomes. As a key distinguisher from time-limited collaboratives, ongoing pediatric collaborative improvement networks begin with a plan to persist until aims are achieved and improvement is sustained. Additional evidence from within and external to health care has accrued to support the model since its proposal in 2002, including the Institute of Medicine's vision for a Learning Healthcare System. Required network infrastructure systems and capabilities have been delineated and can be used to accelerate the spread of the model. Pediatric collaborative improvement networks can serve to close the quality gap, engage patients and caregivers in shared learning, and act as laboratories for accelerated translation of research into practice and new knowledge discovery, resulting in improved care and outcomes for children.


Davies M.A.,United Medical Systems
Cancer Journal | Year: 2012

The PI3K (phosphatidylinositol 3-kinase)-AKT pathway is one of the most important signaling networks in cancer. There is growing evidence that activation of this pathway plays a significant role in melanoma, frequently in the setting of concurrent activation of RAS-RAF-MEK-ERK signaling. This evidence includes the identification of genetic and epigenetic events that activate this pathway in melanoma cell lines and clinical specimens. In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance. The availability of many inhibitors against the PI3K-AKT pathway is rapidly leading to the development of trials that will ultimately determine its clinical significance in this disease. The rational development of such therapies will be facilitated by strategies that utilize the growing understanding of the complexity of the regulation and roles of this pathway. Copyright © 2012 by Lippincott Williams &Wilkins.


Stefater 3rd. J.A.,United Medical Systems
Blood | Year: 2013

The treatment of festering wounds is one of the most important aspects of medical care. Macrophages are important components of wound repair, both in fending off infection and in coordinating tissue repair. Here we show that macrophages use a Wnt-Calcineurin-Flt1 signaling pathway to suppress wound vasculature and delay repair. Conditional mutants deficient in both Wntless/GPR177, the secretory transporter of Wnt ligands, and CNB1, the essential component of the nuclear factor of activated T cells dephosporylation complex, displayed enhanced angiogenesis and accelerated repair. Furthermore, in myeloid-like cells, we show that noncanonical Wnt activates Flt1, a naturally occurring inhibitor of vascular endothelial growth factor-A-mediated angiogenesis, but only when calcineurin function is intact. Then, as expected, conditional deletion of Flt1 in macrophages resulted in enhanced wound angiogenesis and repair. These results are consistent with the published link between enhanced angiogenesis and enhanced repair, and establish novel therapeutic approaches for treatment of wounds.

Loading United Medical Systems collaborators
Loading United Medical Systems collaborators